Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $182.00 at Piper Sandler

Sarepta Therapeutics (NASDAQ:SRPT) had its price target decreased by Piper Sandler from $200.00 to $182.00 in a report published on Wednesday,Benzinga reports. Piper Sandler currently has an overweight rating on the biotechnology company’s stock.

SRPT has been the topic of a number of other reports. Robert W. Baird lowered their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Royal Bank of Canada restated an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 21st. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Raymond James reissued an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Finally, Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $137.94 on Wednesday. Sarepta Therapeutics has a 12-month low of $78.67 and a 12-month high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm has a market capitalization of $13.18 billion, a price-to-earnings ratio of 110.35 and a beta of 0.81. The business has a 50 day simple moving average of $121.90 and a 200 day simple moving average of $131.39.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This represents a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SRPT. Innealta Capital LLC purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at $31,000. New Covenant Trust Company N.A. acquired a new stake in Sarepta Therapeutics during the first quarter valued at $32,000. Sunbelt Securities Inc. grew its stake in Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares in the last quarter. Huntington National Bank increased its position in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares during the last quarter. Finally, Nkcfo LLC purchased a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth about $43,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.